Wearable-Biomarker Evidence Recovery Authority — Preventive Cardiology

The mandate

A member-review sample found that device firmware, wear position, signal-quality filters, biomarker algorithm versions and care-navigation thresholds did not always align at the time an outreach recommendation was generated. Clinicians reviewed affected referrals and protected care, but the digital-biomarker executive left unexpectedly. The network must restore an explainable evidence chain before extending the service to new employer populations.

The interim must join within three weeks for nine months, leading affected-member review, release control, device-partner remediation, two cohort cycles and successor induction. A permanent search opens after a seventy-day signal-quality baseline. Five weeks are reserved for overlap; the assignment will not extend for new disease pathways, insurance product design or general electronic-record replacement.

At handover, every priority recommendation must resolve member consent, device and firmware, wear context, raw-signal availability, quality treatment, biomarker algorithm, reference interval, threshold, outreach, clinician review and correction. The successor must command unseen firmware-change and low-adherence exercises and accept remaining device, population-representation and historical raw-signal debt.

The authority may suspend algorithms or device integrations, quarantine recommendations, require clinical review, set release gates, direct the approved ₹52 crore recovery and appoint temporary control leads. Clinicians retain diagnosis, referral and treatment; Quality and Privacy retain formal decisions; employers receive only contracted outputs. The interim cannot change care protocols, eligibility or permanent staffing without approval.

Development of new biomarkers, clinical research conclusions and renegotiation of employer benefits are excluded. The leader may demand calibration and population evidence but cannot treat a wearable signal as diagnosis or force disclosure beyond consent. Recovery is bounded to trustworthy sensing, computation, communication and human review within the existing preventive-cardiology pathway.

Why this seat is open

The sample exposed an operational lineage problem rather than a single faulty device, and the responsible executive’s exit left Clinical, Product and Engineering without one decision owner. Member expansion cannot proceed on manual reconciliation. Temporary leadership will restore controlled releases and prepare a permanent owner while physicians remain fully accountable for care.

What you will own

• Reconstruct affected recommendations across consent, device, firmware, wear context, signal, quality filter, algorithm, threshold, outreach and review.
• Define effective identity and applicability for devices, firmware, algorithms, reference populations and care-navigation rules.
• Decide which integrations and recommendations may resume, require qualification, need clinician review or remain quarantined.
• Command exercises for firmware change, poor adherence, clock drift, missing raw signal, population shift and delayed clinician response.
• Establish member-facing correction and uncertainty language that distinguishes wellness signal, biomarker indication and medical judgement.
• Govern remediation against bounded cohort exposure, signal-quality evidence, reviewed outreach, correction latency and recurring exceptions.
• Transfer command through two cohort cycles and successor acceptance of device, representation and retained-signal limitations.

Candidate qualifications

• Held executive digital-biomarker, remote-monitoring or connected-care platform authority across a scaled clinical or preventive-care service.
• Reconstructed recommendations across sensor hardware, firmware, wear context, signal-quality processing, algorithms and human clinical review.
• Suspended automated outreach when device change, adherence or population evidence made a biomarker interpretation unreliable.
• Worked with cardiologists, Quality, Privacy, employers and device partners without presenting wellness signals as diagnosis or treatment.
• Governed cohort-specific thresholds, correction and member communication under growth, clinical and reputational pressure.
• Handed a recovered connected-care platform to permanent leadership through adversarial firmware and adherence exercises.

Non-negotiables

• Available within three weeks for Mumbai leadership and travel to selected clinics and device-partner review sessions.
• Has governed production wearable or physiological-sensing evidence in a real care pathway; fitness-app leadership is insufficient.
• No undisclosed interest in wearable, biomarker, laboratory, care-navigation or analytics suppliers inside the service.
• Will preserve consent and clinician authority even where manual review slows employer-member expansion.

1. 49 words maximum. State your Mumbai availability and one wearable recommendation you bounded after a device or algorithm change.
2. 49 words maximum. How did you distinguish a biomarker signal from a clinical referral or diagnosis in member communication?
3. 49 words maximum. Which unseen firmware and adherence scenario would qualify permanent leadership before handover?